Deltazym® APS protease improves process economics in corn ethanol production
Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that the Company will introduce Deltazym® APS protease for use in corn ethanol operations, at the upcoming 2013 International Fuel Ethanol Workshop (FEW) to be held June 10 – 13, 2013 in St. Louis, MO.
Deltazym® APS protease is designed to enhance ethanol operations by improving yeast health for more efficient fermentations, while reducing the use of urea and emulsion breakers providing for improved ethanol plant profitability. The product has also been seen to improve corn oil production and ethanol yield in trials and is effective under low pH conditions. The Company expects to begin selling this product in June of 2013.
“Deltazym® APS is an important addition to our current grain processing product portfolio,” said Janet Roemer, Chief Operating Officer at Verenium. “Now more than ever, corn ethanol plants are looking for innovative ways to minimize processing costs and maximize yields. Much like our other grain processing enzyme products, this new product can offer corn ethanol producers multiple operational advantages for enhanced profitability.”
To learn more about Deltazym® APS protease and Verenium’s other grain processing enzyme products visit booth #715 at FEW. In addition, Verenium’s Director Business Strategy and Marketing, Kulinda Davis, Ph.D, will present on proteases for enhanced operations at FEW as part of Track 1: Production and Operations, on Tuesday, June 11, 2013 at 1:30 PM CT.
Deltazym® APS protease is an acid protease enzyme produced by fermentation of a selected strain of Aspergillus niger and can be used in starch-to-fuel ethanol operations to hydrolyze proteins to amino acids under low pH conditions. Deltazym® APS protease has demonstrated advantages in improving fermentation rates and ethanol yields while reducing the use of urea and emulsion breakers. Deltazym® APS protease is a registered product of WeissBioTech GmbH and is distributed in the United States by Verenium.
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes. Verenium’s tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets. Read more at www.verenium.com.
Statements in this press release that are not strictly historical are “forward-looking” and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to Verenium’s technology, products and product candidates (including, in each case, their value, potential for revenue growth and expected near-term and longer term revenue)and product pipeline (including the timing for commercial launch of any product candidates), lines of business, operations (including Verenium’s ability to successfully negotiate and enter into future collaborations and partnerships), capabilities, commercialization activities, customer adoption rates, industry conditions, future financial performance (including all financial guidance), and near-term and longer-term growth and prospects. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium’s strategic focus, technologies, products and product candidates and product pipeline (including Verenium’s ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, and market demand for those products and product candidates), dependence on patents and proprietary rights, protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium’s dependence on manufacturing and/or license agreements, its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium’s technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture or partnership agreements and licenses on a timely basis or at all, and risks and other uncertainties more fully described in Verenium’s filings with the Securities and Exchange Commission, including, but not limited to, Verenium’s annual report on Form 10-K for the year ended December 31, 2012 and any updates contained in its subsequently filed quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.
For more information on: Verenium